Oppenheimer Reiterates Perform Rating on Day One Biopharmaceuticals (DAWN): "management made the right call to sell now"
Tweet Send to a Friend
Oppenheimer analyst Matt Biegler reiterated a Perform rating on Day One Biopharmaceuticals (NASDAQ: DAWN)The analyst commented, "Day One announced today ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
